用于筛查临床用血和组织制品的疟疾抗体检测方法的评估。
Evaluation of a malarial antibody assay for use in the screening of blood and tissue products for clinical use.
作者信息
Kitchen A D, Lowe P H J, Lalloo K, Chiodini P L
机构信息
National Transfusion Microbiology Reference Laboratory, National Blood Service, London, UK.
出版信息
Vox Sang. 2004 Oct;87(3):150-5. doi: 10.1111/j.1423-0410.2004.00561.x.
BACKGROUND AND OBJECTIVES
A new recombinant Plasmodium antigen enzyme immunoassay (EIA) for the detection of malarial antibodies was evaluated for the screening of 'malaria-risk' blood and tissue donations.
MATERIALS AND METHODS
A total of 13,269 donor and patient samples were tested by both the EIA and the standard diagnostic antibody immunofluorescence test (IFAT).
RESULTS
A total of 114/138 (82.6%) samples from patients with P. falciparum and 11/13 (84.6%) samples from patients with P. vivax tested positive. A total of 714/13,053 (5.47%) samples from donors identified as 'malaria risk', owing to residency or travel, were reactive in the EIA.
CONCLUSIONS
The assay is more sensitive than a previously implemented malarial antibody EIA (73% in acute P. falciparum and 56% in acute P. vivax infections). The sensitivity of this new EIA is comparable to that of the IFAT, and the specificity is sufficient to screen 'malaria-risk' donors.
背景与目的
评估一种用于检测疟疾抗体的新型重组疟原虫抗原酶免疫测定法（EIA），以筛查“疟疾风险”血液和组织捐赠。
材料与方法
采用EIA和标准诊断性抗体免疫荧光试验（IFAT）对总共13269份供体和患者样本进行检测。
结果
恶性疟患者的114/138份样本（82.6%）和间日疟患者的11/13份样本（84.6%）检测呈阳性。因居住或旅行被确定为“疟疾风险”的供体的13053份样本中，共有714份（5.47%）在EIA中呈反应性。
结论
该测定法比之前实施的疟疾抗体EIA更敏感（急性恶性疟感染中为73%，急性间日疟感染中为56%）。这种新型EIA的敏感性与IFAT相当，特异性足以筛查“疟疾风险”供体。
Zotero 插件